GlassScriptPhysician profile
Augustyna Patrycja Gogoj
NPI 1063974616
$1,596.56
in general payments reported to CMS, 2019-2025
15 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $166 · 2024: $791 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Travel and Lodging: $177 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.98 |
| Travel and Lodging | $176.52 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $713.46 | 2023-2025 | Titan |
| Sumitomo Pharma America, INC. | $172.62 | 2024-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $147.42 | 2023-2024 | Axonics, Bulkamid |
| Abbvie INC. | $136.69 | 2024-2025 | |
| Boston Scientific Corporation | $101.77 | 2025 | Axonics, Ams 700 |
| Verity Pharmaceuticals INC. | $87.13 | 2025 | Trelstar, Tlando |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Immunitybio, INC. | $30.26 | 2025 | |
| Medtronic, INC. | $29.42 | 2024 | Interstim |
| 180 Medical, INC. | $27.75 | 2025 | Gentlecath |
| Merck Sharp & Dohme LLC | $27.29 | 2023 | Keytruda, Lynparza |
| Pfizer INC. | $26.27 | 2025 | |
| Endo USA, INC. | $25.67 | 2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $19.80 | 2024 | Adstiladrin |
| Vertex Pharmaceuticals Incorporated | $15.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustyna Gogoj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.